Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read…
The purchase allows the brain–computer interface company to oversee the end-to-end fabrication of its microelectrode array while iterating quickly on…
Dr. Mario Capecchi, Nobel Laureate at University of Utah, to Deliver Keynote on Research to Understand Symptoms Prevalent in Individuals…
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile…
Preliminary Research on Late Life Depression and Accelerated Depression Treatment Protocol will be FeaturedBURLINGTON, Mass. and JERUSALEM, Sept. 27, 2023…
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure LX9211 is an investigational, non-opioid treatment for diabetic peripheral…
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed…
Brain Canada’s Future Leaders in Canadian Brain Research program to support 28 early-career researchers this year The 2022 Future Leaders…
New Approach to Measuring Impact of Counselling to Deliver Next Generation Care to Mental Health Sufferers in North AmericaVancouver, British…
Company’s Chief Medical Officer and FDA veteran receives distinguished award for notable contributions to clinical researchDURHAM, N.C., Sept. 20, 2023…